TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26080912

Group type: EXPERIMENTAL
Intervention: Group A (270 mgI/ml of contrast medium, 80 kVp tube voltage scanning and 50% ASiR)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Group B (350 mgI/ml of contrast medium, 120 kVp routine tube voltage)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 58

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 58
Study: 23271695

Group type: EXPERIMENTAL
Intervention: Combination of bioactive food ingredients (epigallocatechin gallate, capsaicins, piperine, L-carnitine)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 21733979

Group type: EXPERIMENTAL
Intervention: Comprehensive spirometry training
Number of subjects: 397

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 397
Study: 19840309

Group type: EXPERIMENTAL
Intervention: Twice-daily pimecrolimus cream 1%
Number of subjects: 268

Group type: COMPARATOR
Intervention: Once-daily pimecrolimus cream 1%
Number of subjects: 268
Study: 16495416

Group type: EXPERIMENTAL
Intervention: Dynamic single operator (D1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Dynamic two operator (D2)
Number of subjects: 44
Study: 15286858

Group type: EXPERIMENTAL
Intervention: Creatine supplement (20 g of Creatine monohydrate for 14 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (maltodextrine)
Number of subjects: 14
Study: 16978630

Group type: EXPERIMENTAL
Intervention: Infected men
Number of subjects: 263

Group type: COMPARATOR
Intervention: Uninfected men
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Infected women
Number of subjects: 263

Group type: COMPARATOR
Intervention: Uninfected women
Number of subjects: 263
Study: 10394855

Group type: EXPERIMENTAL
Intervention: Daily doses of 100 mg for 3 months (fingernail) or 4 months (toenail) - Group A
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intermittent pulse therapy with daily doses of 400 mg - Group B
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intermittent pulse therapy with daily doses of 300 mg - Group C
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intermittent pulse therapy with daily doses of 200 mg - Group D
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Further treatment with daily doses of 400 mg for non-cured patients
Number of subjects: 153
Study: 8688391

Group type: EXPERIMENTAL
Intervention: Pre-eclampsia with intrauterine growth retardation (IUGR)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pre-eclampsia without IUGR
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nonpre-eclamptic pregnancy
Number of subjects: 66
Study: 1863726

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP) 0.3 microgram/kg over 15 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 15
Study: 7117360

Group type: EXPERIMENTAL
Intervention: Prednisone (PN 30 + 30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Deflazacort (DF 36 + 36 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison between PL and PN
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Comparison between DF and PN
Number of subjects: 12
Study: 31208680

Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance-based self-help approach (book)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 117
Study: 30232528

Group type: EXPERIMENTAL
Intervention: GHB 50 mg/kg orally
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27090032

Group type: EXPERIMENTAL
Intervention: Repeated Sprint Training (RST, at 90% HRpeak)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MCT, at 70% HRpeak)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both RST and MCT
Number of subjects: 13
Study: 24601887

Group type: EXPERIMENTAL
Intervention: 50 mg of plain 1% 2-chloroprocaine (Group C, n = 66)
Number of subjects: 130

Group type: COMPARATOR
Intervention: 10 mg of plain 0.5% bupivacaine (Group B, n = 64)
Number of subjects: 130
Study: 20015098

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (4.0 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 11
Study: 19537284

Group type: EXPERIMENTAL
Intervention: C/BPO HE (clindamycin 1%-BPO 5% topical gel with hydrating excipients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: C/BPO (clindamycin 1%-BPO 5% topical gel without hydrating excipients)
Number of subjects: 20
Study: 17888700

Group type: EXPERIMENTAL
Intervention: Augmented BMD report containing 5‐yr and lifetime absolute hip fracture risk estimates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic BMD report
Number of subjects: 0
Study: 15249367

Group type: EXPERIMENTAL
Intervention: Vision restoration/rehabilitation intervention (details not specified)
Number of subjects: 1591
Study: 11552769

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1056
Study: 9882080

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg (37 mg of the trometamol salt)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ketoprofen 50 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dexketoprofen free acid 25 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg (repeated dose, twice daily for 7 days)
Number of subjects: 54
Study: 8002761

Group type: EXPERIMENTAL
Intervention: Computer format of the Sickness Impact Profile (SIP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Paper format of the Sickness Impact Profile (SIP)
Number of subjects: 48
Study: 2911205

Group type: EXPERIMENTAL
Intervention: Daunorubicin (50 mg/m2, IV) on days 1‐3; cytarabine (Ara‐C) (25 mg/m2, IV) bolus, followed by 160 mg/m2 as a continuous IV infusion daily for 5 days and 6‐thioguanine (6‐TG) (100 mg/m2 po) every 12 hr daily for 5 days (DAT)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Amsacrine (190 mg/m2, IV) on days 1‐3 with Ara‐C and 6‐TG at the above doses (AAT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Maintenance therapy (alternating cycles of vincristine/methotrexate, cyclophosphamide/6‐TG, daunorubicin/hydroxyurea and Ara‐C/6‐TG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 96
Study: 30650341

Group type: EXPERIMENTAL
Intervention: Monopolar coagulation
Number of subjects: 199

Group type: COMPARATOR
Intervention: Monopolar cut
Number of subjects: 199
Study: 28821468

Group type: EXPERIMENTAL
Intervention: Stepped care behavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26493430

Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 23993727

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 21270183

Group type: EXPERIMENTAL
Intervention: Structured Testing Group (STG) with enhanced usual care and structured self-monitoring of blood glucose (SMBG)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Active Control Group (ACG) with enhanced usual care
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Structured Testing Group (STG)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Both groups (STG and ACG)
Number of subjects: 483
Study: 19882578

Group type: COMPARATOR
Intervention: Conventional phacoemulsification (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification (OZil, group 2)
Number of subjects: 100
Study: 16798668

Group type: EXPERIMENTAL
Intervention: Cell saver group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 12558839

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 0
Study: 10792161

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 51
Study: 9348577

Group type: EXPERIMENTAL
Intervention: Cisplatin/5-FU (group 1): Cisplatin 100 mg/m2 on day 1 followed by continuous infusion of 5-FU 1,000 mg/m2/day on days 2-6, repeated every 21 days for four cycles.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cisplatin/UFT (group 2): Cisplatin 100 mg/m2 on day 1 followed by oral UFT 300 mg/m2/day on days 2-20, repeated every 21 days for four cycles.
Number of subjects: 67
Study: 8396102

Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg (maximum 500 mg) for three days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Penicillin V at a dose of 125 mg or 250 mg qid for ten days
Number of subjects: 96
Study: 3701861

Group type: EXPERIMENTAL
Intervention: Classical conditioning therapy (54 10‐min immersions of both hands in water at 43 degrees C, with whole‐body exposure to cold air at 0 degrees C, three times per day, 3 days per week, for 6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (eight sessions of electromyograph feedback while listening to relaxation tapes, followed by 10 sessions of digital thermal feedback while listening to relaxation tapes)
Number of subjects: 0
Study: 29066464

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (162 mg weekly)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 27602924

Group type: EXPERIMENTAL
Intervention: Preoperative radiation (50 Gy per 25 fractions) and 5‐fluorouracil infusion (arm A)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Preoperative radiation (50 Gy per 25 fractions) and 5‐fluorouracil infusion combined with oxaliplatin (arm B)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Preoperative chemotherapy with 5‐fluorouracil and oxaliplatin without radiation (arm C)
Number of subjects: 318
Study: 23733529

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study: 23584671

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20811556

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (higher than 300 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentosan polysulfate (300 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (duration of therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Successful therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptom improvement with therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium Sensitivity Test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: O'Leary-Sant Interstitial Cystitis Symptom Index
Number of subjects: 0
Study: 18171211

Group type: EXPERIMENTAL
Intervention: Long-term daily aspirin use
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 16155280

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (E+P) therapy, n = 437
Number of subjects: 835

Group type: COMPARATOR
Intervention: Placebo, n = 398
Number of subjects: 835
Study: 12855528

Group type: EXPERIMENTAL
Intervention: Virtual outreach (joint teleconsultation)
Number of subjects: 3170

Group type: COMPARATOR
Intervention: Standard outpatient appointments
Number of subjects: 3170
Study: 10539778

Group type: EXPERIMENTAL
Intervention: Group 1: iron + folate (60 mg and 250 microg, respectively) daily for 3 mo, then folate (250 microg) weekly for 4 mo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Group 2: folate daily, and 60 mg iron only once weekly for 3 mo, then weekly iron + folate for 4 mo
Number of subjects: 116

Group type: COMPARATOR
Intervention: Group 3: folate daily for 3 mo and then weekly for 4 mo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation over 7 mo (30 doses)
Number of subjects: 116
Study: 8690193

Group type: EXPERIMENTAL
Intervention: Oral lactulose (20 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intracolonic lactose (20 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intracolonic SCFAs (54 mmol/180 mL and 90 mmol/180 mL)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Plasma oxyntomodulin‐like immunoreactivity and glucagon‐like peptide 1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Peptide YY
Number of subjects: 13
Study: 1879271

Group type: EXPERIMENTAL
Intervention: modified Ayre spatula plus Zelsmyr Cytobrush (90 cases)
Number of subjects: 192

Group type: COMPARATOR
Intervention: modified Ayre spatula plus bulb aspirator (102 cases)
Number of subjects: 192
Study: 7049781

Group type: EXPERIMENTAL
Intervention: Neutral soluble human (semi-synthetic) insulin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Porcine insulin
Number of subjects: 6
Study: 28635364

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control
Number of subjects: 234
Study: 26946343

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) every 8 weeks for 200 weeks
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo every 8 weeks for 200 weeks
Number of subjects: 297
Study: 24513806

Group type: EXPERIMENTAL
Intervention: Indomethacin plus sublingual nitrate (group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Indomethacin plus sublingual placebo (group B)
Number of subjects: 300
Study: 23154692

Group type: EXPERIMENTAL
Intervention: Attendance at rehabilitation residence for pregnant women with substance-use disorders
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Attendance at prenatal clinic for women with substance-use disorders
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no attendance at rehabilitation residence)
Number of subjects: 96
Study: 20224057

Group type: EXPERIMENTAL
Intervention: Adhesive capsulitis (AC)
Number of subjects: 10935

Group type: COMPARATOR
Intervention: Control group (randomly selected, 32,805 patients)
Number of subjects: 10935
Study: 18440400

Group type: EXPERIMENTAL
Intervention: Instructed social support from their partner
Number of subjects: 63

Group type: COMPARATOR
Intervention: No social support
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Secure attachment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination of social support and secure attachment
Number of subjects: 63
Study: 16158207

Group type: EXPERIMENTAL
Intervention: Detralex 500 mg (2 tablets 3 times daily for 5 days after the operation)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no Detralex treatment)
Number of subjects: 63
Study: 12568734

Group type: EXPERIMENTAL
Intervention: 0.625 mg OD of natural conjugated estrogens during 4 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10800013

Group type: EXPERIMENTAL
Intervention: Interactive, school-based self-esteem education program
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control group (scheduled personal development and health class)
Number of subjects: 470
Study: 8972794

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 115
Study: 1454434

Group type: EXPERIMENTAL
Intervention: APDT (Acellular Pertussis Vaccine with Lederle Diphtheria and Tetanus Toxoids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: APDT-T/J (Commercially available Japanese Takeda vaccine)
Number of subjects: 0
Study: 3931661

Group type: EXPERIMENTAL
Intervention: Meptazinol 1 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pethidine 0.5 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pethidine 1 mg kg‐1
Number of subjects: 30
Study: 30737551

Group type: EXPERIMENTAL
Intervention: S-1 adjuvant monotherapy
Number of subjects: 355
Study: 30041885

Group type: EXPERIMENTAL
Intervention: Breastfed group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Powdered formula group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no feeding)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bottle-fed mother's milk group
Number of subjects: 100
Study: 26826629

Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 54
Study: 24942703

Group type: EXPERIMENTAL
Intervention: strength training + a-tDCS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: a-tDCS alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: strength training + sham-tDCS
Number of subjects: 10

Group type: COMPARATOR
Intervention: tDCS alone
Number of subjects: 10
Study: 22054659

Group type: EXPERIMENTAL
Intervention: ONCAB
Number of subjects: 2103

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 2103

Group type: EXPERIMENTAL
Intervention: POAF
Number of subjects: 2103
Study: 21055664

Group type: EXPERIMENTAL
Intervention: Desensitization with cow's milk (CM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Soy milk (control)
Number of subjects: 30
Study: 17693380

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 3029
Study: 15818609

Group type: EXPERIMENTAL
Intervention: Mental Health Treatment Court (MHTC)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 235
Study: 10851775

Group type: EXPERIMENTAL
Intervention: Foot massage (10 minutes, 5 minutes per foot)
Number of subjects: 87
Study: 9291724

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Therapy for Sexually Abused Preschoolers (CBT‐SAP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nondirective supportive therapy (NST)
Number of subjects: 43
Study: 8241988

Group type: EXPERIMENTAL
Intervention: i.v. immunoglobulin (1.0 g/kg once weekly for 120 days after transplant) plus CMV‐seronegative blood products
Number of subjects: 51

Group type: COMPARATOR
Intervention: CMV‐seronegative blood products alone
Number of subjects: 51
Study: 3516097

Group type: EXPERIMENTAL
Intervention: Ceruletide (cholecystokinin decapeptide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fasting bile acid levels
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase
Number of subjects: 20
Study: 29488798

Group type: EXPERIMENTAL
Intervention: Counselling on a heart-healthy diet and physical activity (PA) plus access to a smartphone app for 3 months.
Number of subjects: 833

Group type: COMPARATOR
Intervention: Counselling on a heart-healthy diet and physical activity (PA) only (Control Group).
Number of subjects: 833
Study: 25834945

Group type: EXPERIMENTAL
Intervention: Multimedia consent process
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Enhanced interactivity
Number of subjects: 200

Group type: COMPARATOR
Intervention: Multimedia condition
Number of subjects: 200
Study: 23746872

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no prednisolone)
Number of subjects: 81
Study: 21180674

Group type: EXPERIMENTAL
Intervention: Garlic extract mouthwash (garlic extract + water + sorbitol + spearmint oil)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.2%) mouthwash
Number of subjects: 45

Group type: COMPARATOR
Intervention: Negative control (water + sorbitol + spearmint oil)
Number of subjects: 45
Study: 18635504

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia/analgesia supplementation
Number of subjects: 177

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Age and hypertension interaction
Number of subjects: 177
Study: 16360599

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 14668456

Group type: EXPERIMENTAL
Intervention: Four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Four-drug regimen containing zidovudine, lamivudine, nelfinavir, and efavirenz
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Four-drug regimen
Number of subjects: 980

Group type: COMPARATOR
Intervention: Three-drug regimen containing zidovudine, lamivudine, and efavirenz
Number of subjects: 980
Study: 11077325

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen‐Rossetti total fundic wrap with intact short gastric vessels
Number of subjects: 99

Group type: COMPARATOR
Intervention: Complete division of short gastric vessels
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both procedures (intact vessels and division)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Division of short gastric vessels
Number of subjects: 99
Study: 9024266

Group type: EXPERIMENTAL
Intervention: Recombinant human insulin-like growth factor I (rhIGF-I) at 120 micrograms/kg BW twice daily (n = 15)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Recombinant human insulin-like growth factor I (rhIGF-I) at 80 micrograms/kg BW twice daily (n = 7)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Growth hormone (GH) treatment in idiopathic growth hormone deficiency (GHD) (n = 11)
Number of subjects: 22
Study: 1563538

Group type: EXPERIMENTAL
Intervention: Random urine sample during outpatient visit
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Microbumintest (Ames‐Bayer)
Number of subjects: 209
Study: 3095080

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol electrolyte lavage solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 percent mannitol solution
Number of subjects: 80
Study: 29550780

Group type: EXPERIMENTAL
Intervention: Facility plus community interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Facility-only interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Uganda only)
Number of subjects: 0